Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan Chairman Robert Coury On Lipitor's Future and India/Japan Expansion: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Mylan Inc. CEO Robert J. Coury demonstrated his ability to be a trendsetter when Mylan acquired Matrix Laboratories in 2007 at the highest value - at the time - for an India pharmaceutical company. Though doubted for that move and the next - of buying Merck KGaA's generics business for $6.8 billion, Coury now boasts of establishing a global generics footprint with a one-of-a-kind vertically integrated platform to build maximum operational efficiencies.

You may also be interested in...

Mylan Weighs "Big Bang Or Phased" Products Rollout In India; Significant Workforce Additions Planned

MUMBAI - On a trip to India, Mylan Inc. CEO and Chairman Robert Coury praised the "voluminous contributions" of Indian arm Matrix Laboratories Ltd. in Mylan's global-scale vertical integration drive, but also announced that the company would rebrand Matrix as Mylan as it moves forward with launching Mylan products in India

Teva Buys Japanese Generics Company For $460 Mil.

Teva Pharmaceutical Industries Ltd. announced May 16 that it is acquiring more than half of Japan's third largest generic drugmaker and extending an offer to purchase the remaining portion of the company

FDA Import Alert Lifted, Apotex Says; Will Lipitor ANDA Approvals Be Far Behind?

Apotex’s announcement that FDA is lifting an import alert on products manufactured at two Canadian facilities could be interpreted as a good sign for the near-term availability of Lipitor generics, either from first-filer Ranbaxy Laboratories Ltd. or subsequent ANDA filers.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts